ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.

PF-07921585 is under clinical development by Pfizer and currently in Phase I for Metastatic Colorectal Cancer.

Nearly 200 nations at the Cop28 climate summit in Dubai agreed to the deal, which calls on them to "transition away" from ... who had called for the term "phase out" of fossil fuels to be used ...

Deconfined quantum criticality represents a novel class of phase transitions that fall outside ... material candidates show a weakly-first order transition. Here the authors introduce a Nordic ...